STOCKS TELEGRAPH

Tag: NASDAQ:TGTX

  • TG Therapeutics (TGTX) Sees Significant Stock Surge After Financial Update

    TG Therapeutics (TGTX) Sees Significant Stock Surge After Financial Update

    The most recent business update and financial results announcement from TG Therapeutics, Inc. (NASDAQ: TGTX) is driving the share price higher on the charts. As of the most recent check today, TGTX stock was trading at $34.79, with a 15.62% rise.

    Strong Revenue Growth

    TG Therapeutics reported net product revenue of approximately $313.7 million for the full year, ending on December 31, 2024, and $107.3 million for the fourth quarter. Sales of BRIUMVI in the US were the primary driver of this revenue, which was $103.6 million in the fourth quarter and $310.0 million for the whole year—a remarkable 250% year-over-year rise.

    Growth and Enhanced Patent Portfolio

    The high level of acceptability of BRIUMVI among adult patients with relapsing forms of multiple sclerosis has been credited with TG Therapeutics’ remarkable performance over the past 12 months. By launching BRIUMVI in a number of EU and UK nations, TG Therapeutics expanded its worldwide market reach in partnership with Neuraxpharm. The company’s strategy goal to improve accessibility and spur further growth is in line with the expansion.

    Research and Clinical Developments

    Clinical research has advanced significantly thanks to TG Therapeutics, especially with the continued development of BRIUMVI. The release of five-year results from the open-label extension study of the ULTIMATE I & II Phase 3 trials marked a significant turning point. With an annualized relapse rate of 0.02 in year five, the results showed that 92% of patients were still free from disability progression after five years of therapy.

    Additionally, the study verified that no new unfavorable signals appeared with extended therapy, and the safety profile was stable. The business also recruited patients with Myasthenia Gravis in another Phase 1 research and started a Phase 1 trial assessing subcutaneous ublituximab for relapse multiple sclerosis.

    Strategic Collaboration and Prospects

    In an attempt to broaden its therapeutic offerings, TG Therapeutics and Precision BioSciences, Inc. inked a global licensing agreement for the development and marketing of Precision’s allogeneic CD19 CAR T therapy product, azercabtagene zapreleucel (azer-cel). With a strong pipeline, important partnerships, and strong financial results, TG Therapeutics is well-positioned for continued success as it works toward developing innovative treatments for autoimmune diseases.

  • TG Therapeutics Inc (TGTX) stock soared in the current market trading session; find out why

    TG Therapeutics Inc (TGTX) stock soared in the current market trading session; find out why

    TG Therapeutics Inc. (TGTX) stock soared by 1.71% to the price of $45.04 in the current market at the time of writing. TGTX stock previously closed at $45.83. TGTX stock traded today at a volume of 1.74 million shares. This volume was 0.28 million higher than the average daily volume of 1.42 million shares for the past 3 months. In the last 12 months, TGTX stock soared by 344.09%, however, in the past week the stock moved down by -1.86%. The stock has lost -13.67% in the three previous months, and over the previous six months, an additional 47.36%. Furthermore, TG Therapeutics Inc. is currently valued at $6.72 billion with 124.19 million outstanding shares.

    Operational background of TG Therapeutics Inc.

    TG Therapeutics is a commercial-stage biopharmaceutical company that is focused on designing, acquiring, and commercializing novel and unique treatments to meet the unmet needs of patients. These treatments are specifically for diseases related to autoimmunity as well as B-cell malignancies.  The leading treatments and therapeutics of TGTX include Ublituximab (for treating B-cell non-hodgkin lymphoma, CLL, multiple sclerosis relapsing form), Umbralisib (for treating CLL, marginal zone, and follicular lymphoma), and Cosibelimab (blocker of death-ligand), in addition to having these and many more medicines commercialized, the TGTX stock has an active research pipeline.

    Latest approvals and investigative studies performed at TGTX

    The latest approval received by the company from the FDA is for UKONIQTM which is in medical terms, an oral inhibitor containing P13K delta and CK1-epilson. The company is working on two programs that are currently in phase 3 developments which are meant for the treatment of RMS and CLL along with several phase 1 medicines in the investigational phase.

    TGTX stock announced that it has achieved positive results from Ultimate I & II which were phase 3 studies that were actively controlled and were purposed for the evaluation of ublituximab.  The study ended up with results that concluded that both tests had met their primary endpoint for ublituximab; statistically reduced ARR in 96 week period.

    At the American Academy of Neurology’s 73rd Annual meeting, TXTG will be presenting the results of this study on 17th April 2021. According to Lawrence Steinman, MD, Zimmermann who was the global chair for Ultimate I and II stated that the results of the studies reduced the relapses in the patients as well as reduced the inflammatory activity. The studies also reduced lesions in the brain and chances of disability progressions had a low rate in RMS patients when treated with ublituximab.

    Future prospects of Ublituximab

    The studies tested the efficacy of infusion activity of 450 mg Ublituximab one hour every six months. The results were conducted under special protocol assessment that was made with the FDA. The next aim is to use the results of this study and its efficacy to push for a Biological License submission for ublituximab. This will be targeted for 2021’s third quarter.